Skip to main content

Table 3 APOE polymorphism in T2DM patients with or without CVD

From: Apolipoprotein E gene polymorphism and the risk of cardiovascular disease and type 2 diabetes

Genotype All case CVD- p CVD+ p
T2DM- (n = 211) T2DM+ (n = 247) T2DM- (n = 232) T2DM+ (n = 234)
E2/E2 5 (0.5%) 1 (0.5%) 2 (0.8%) 1.00 1 (0.4%) 1 (0.4%) 1.00
E3/E3 626 (67.7%) 160 (75.8%) 183 (74.1%) 0.67 144 (62.1.5%)## 139 (59.4%)&& 0.56
E4/E4 11 (11.9%) 1 (0.5%) 6 (2.6%) 4 (1.7%) 0.51
E2/E3 83 (8.9%) 24 (11.4%) 16 (6.5%) 0.06 23 (9.9%) 20 (8.5%) 0.63
E2/E4 22 (2.3%) 3 (1.2%) 12 (5.2%) 7 (3.0%) 0.23
E3/E4 177(19.2%) 25 (11.8%) 43 (17.4%) 0.10 46 (19.8%)# 63 (26.9%)&& 0.07
ε2 115 (6.2%) 26 (6.2%) 23 (4.7%) 0.31 37 (7.9%) 29 (6.1%) 0.29
ε3 1512 (81.8%) 369 (87.4%) 425 (86.0%) 0.53 357 (76.9%)## 361 (77.1%)&& 0.94
ε4 221 (12.0%) 27 (6.4%) 46 (9.3%) 0.11 70 (15.1%)## 78 (16.7%)&& 0.51
  1. #p-value: comparison between CVD + T2DM- and controls
  2. &p-value: comparison between CVD + T2DM- and controls